leisure time -WSS

leisure time

author：comprehensive 2025-10-01 11:45:41 - browse：19723

Grail spent more than $1 million last quarter lobbying Congress, underscoring the urgency of the company’s bid to secure Medicare coverage for its pricey blood-based cancer screening test that has been on the market for over a year but is not widely used.

A recently posted lobbying report indicates that, during the fourth quarter of last year, the biotech spent $1.07 million on “issues related to oncology and multi-cancer early detection,” including House and Senate bills that would allow Medicare to cover multi-cancer screening tests. That figure has been rising; during the fourth quarter of 2021, the company spent $470,000 on lobbying. That’s far more than cancer and genetic testing biotechs such as Guardant Health, Myriad Genetics, and Tempus, which spent anywhere from $90,000 to nearly $300,000 on lobbying last quarter.

The growing investment in lobbying elected officials comes at a time when Grail is looking to make its test, Galleri, available to a broader swath of the population. The test, launched in 2021, can detect early signs of more than 50 cancers among people who don’t have symptoms. That’s because cancer cells release bits of DNA into the bloodstream, and Galleri spots telltale modifications to this DNA.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： The cancer drug shortage isn’t new — and neither are the solutions
Next article： First recipient of genetically engineered pig kidney has died

WSS

Software glitch causes Tandem insulin pump to shutdown, FDA warns

Gilead acquiring CymaBay and its liver disease drug for $4.3 billion

Medicare says breakthrough device reimbursement rule to come by summer

Brain worms: The science behind RFK Jr.'s parasitic infection

Senators start work on Medicare physician payment reform

To avoid data mishandling cases, universities eye AI and other tools

knowledge

leisure time

hotspot

Anesthesiologist group: stop taking Ozempic before surgery

How to improve immunocompromised access to mAb treatments

Trump demands the U.S. pay no more for drugs than other countries … again

Bird flu outbreak in cows is latest avian flu curveball

Moonlake's readout produced a cash windfall. Risks remain

Readout LOUD podcast: What to know about H5N1 bird flu

Drug repurposing or repositioning? The language matters

Medicare says breakthrough device reimbursement rule to come by summer

New air purifier tech could be key to improving indoor air quality

Making AI in medicine accessible to smaller, and rural hospitals

hotspot

Readout LOUD podcast: What to know about H5N1 bird flu

How digital tools helped lower hypertension in marginalized patients

Study: AI not yet building 'n

Telehealth startups turn to complex chronic diseases

The dental labor crisis is a moment of opportunity

Bird flu outbreak in cows is latest avian flu curveball

hotspot

entertainment

focus

leisure time